Medikamentöse Therapie des Pankreaskarzinoms

Beim Pankreaskarzinom ist es in den vergangenen Dekaden kaum gelungen, die Sterberate nennenswert zu senken. Neue Studien zeigen jetzt aber deutliche Verbesserungen in verschiedenen Situationen. Ein aktueller Überblick.

• Literatur

• 1 Oettle H, Post S, Neuhaus P. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277
• 2 Ueno H, Kosuge T, Matsuyama Y. et al. A randomised phase III trial comparing gemcitabine with surger – only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101: 908-915
• 3 Neoptolemos JP, Stocken DD, Bassi C. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304: 1073-1081
• 4 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
• 5 Conroy T, Hammel P, Hebbar M. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018; 379: 2395-2406
• 6 Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med 2014; 371: 1039-1049
• 7 Neuhaus P, Riess H, Post S. et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2016; 26
• 8 Schlitter A, Esposito I. Definition of Microscopic Tumor Clearance (R0) in Pancreatic Cancer Resections. Cancers 2010; 2: 2001-2010
• 9 Tzeng CW, Tran Cao HS, Lee JE. et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 2014; 18: 16-24
• 10 Versteijne E, Vogel JA, Besselink MG. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 2018; 105: 946-958
• 11 van Tienhoven G, Versteijne E, Suker M. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol 2018; 36
• 12 Murphy JE, Wo JY, Ryan DP. et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4: 963-969
• 13 Conroy T, Desseigne F, Ychou M. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011; 364: 1817-1825
• 14 Von Hoff DD, Ervin T, Arena FP. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013; 369: 1691-1703
• 15 Kim SS, Signorovitch J, Yang H. et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States. J Clin Oncol 2018; 36
• 16 Dahan L, Phelip JM, Le Malicot K. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial. J Clin Oncol 2018; 36
• 17 Abrams TA, Meyer G, Meyerhardt JA. et al. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Oncologist 2017; 22: 925-933
• 18 Wang-Gillam A, von Hoff D, Siveke J. et al. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. J Clin Oncol 2017; 35: 689-690
• 19 Zhang Y, Hochster H, Stein S. et al. Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity. Exp Hematol Oncol 2015; 4: 29 . doi:10.1186/s40164-015-0025-y
• 20 Zhang H, Kellett C, Lambert PJ. et al. Efficacy and tolerability of second-line nab-paclitaxel and gemcitabine (NG) after failing first-line FOLFIRINOX in patients (pts) with advanced pancreatic cancer (APC): A single-institution experience. J Clin Oncol 2017; 35
• 21 Sohal DPS, Kennedy EB, Khorana A. et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018; 36: 2545-2556
• 22 www.onkopedia.com/de/onkopedia/guidelines/pankreaskarzinom
• 23 Drilon A, Laetsch TW, Kumma S. et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med 2018; 378: 731-739
• 24 Syngal S, Brand RE, Church JM. et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223-226
• 25 NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. V2.2018. https://nccn.org/professionals/physician_gls/default.aspx . 2018// NCCN Guidelines BRCA-Related Breast and/or Ovarian Cancer Syndrom Version 1.2018
• 26 Golan T, Kanji ZS, Epelbaum R. et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014; 111: 1132-1138
• 27 Kaufman B, Shapira-Frommer R, Schmutzler R. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-250